Video

Dr. Klein on Precision Medicine for Prostate Cancer

Author(s):

Eric Klein, MD

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

Eric Klein, MD, professor of Surgery, Lerner College of Medicine, Cleveland Clinic, discusses precision medicine in patients with prostate cancer.

The prostate cancer field has entered the precision medicine era, explains Klein. There are now clinically significant tools in all the different spaces in prostate cancer, such as better screening and tests for the tumor.

Related Videos
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami
Richard Kim, MD, Moffitt Cancer Center
Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.
David Rimm, MD, PhD, discusses current HER2 immunohistochemistry assays that are used in the management of breast cancer, and their shortcomings.
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Related Content
FDA
November 19th 2024

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

177Lu-PSMA-I&T in PSMA+ mCRPC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 13th 2024

177Lu-PSMA-I&T Meets rPFS End Point in PSMA+ mCRPC

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
November 12th 2024

Revumenib Meets CR/CRh End Point in NPM1+ R/R AML